2024.06.27-29    We exhibited the data of “efficacy of the binding-avidity of SARS-CoV-2 IgG in protective immunity” at the 98th Annual Meeting of the Japanese Society of Infectious Diseases (Kobe International Conference Center/Kobe International Exhibition Hall No. 1).

2024.05.17    Next Generation Health Tech Startup Development Support Project supported by the Japan Agency for Medical Research and Development (AMED) has been adopted.

2023.11.18-19    We exhibited the data of “efficacy of the binding-avidity of IgE in allergic reaction sensitivity” at the 60th Annual Meeting of the Japanese Society of Pediatric Allergy (Miyakomesse, Kyoto).

2023.04.28-30    We exhibited the data of “efficacy of the binding-avidity of SARS-CoV-2 IgG in protective immunity” at the 97th Annual Meeting of the Japanese Society of Infectious Diseases (Pacifico Yokohama North).

2022.11.12-13    We exhibited the data of “efficacy of the binding-avidity of IgE in allergic reaction sensitivity” at the 59th Annual Meeting of the Japanese Society of Pediatric Allergy (Okinawa Convention Center, Laguna Garden Hotel).

2022.11.03-05    We exhibited the data of “efficacy of the binding-avidity of SARS-CoV-2 IgG in protective immunity” at the 92nd Western Japan Regional Meeting of the Japanese Society of Infectious Diseases (Dejima Messe Nagasaki).

2022.10.01    Added to the list of new commissioned analyses: Antigen avidity antibody titer assay of SARS-CoV-2 (COVID-19)S1 protein-specific IgG antibody.

2022.07.19    A research project to promote the development of innovative drugs for emerging and reemerging infectious diseases has been adopted to the Japan Agency for Medical Research and Development (AMED).

2020.09.03    A project to develop technology of antigen avidity antibody titer assay to viruses and other infectious diseases has been adopted to the National Institute of Biomedical Research and Innovation (NIBIO) foundation.

2020.07.15     IgSensor AMERIC🄬 Specific IgE" was certified by PMDA as an in vitro diagnostic product.

2020.04    Registration status update of manufacturer of toxic and deleterious substances.

2020.03     Registration status update of in vitro diagnostics manufacturer.

2019.08.29    The FY2019 Technology Development Project for Advanced Medical Devices and Systems (Program name: Project for Development of Advanced Medical Devices and Systems) has been adopted to the National Institute of Biomedical Research and Innovation (NIBIO).

2019.04.01    A project to measure the specific antibodies in blood samples (6-year-old children) for the "National Survey on Children's Health and the Environment (Eco Chill Survey) Detailed Survey" conducted by the Ministry of the Environment, Japan. (Matters related to DCP chip) has been adopted.

2018.09    A project of SF-10 adjuvant has been adopted by the Japan Agency for Medical Research and Development (AMED) FY 2008 Industry-Academia Collaboration Medical Innovation Creation Program - Basic Scheme (ACT-M).

2017.06.18    We exhibited the data of “efficacy of the binding-avidity of IgE in allergic reaction sensitivity” at the 66th Annual Meeting of the Japanese Society of Allergology (Tokyo International Forum: June 16-18, 2017).

2017.06.10    Financial Report (electronic public notice version) has been added to the Corporate Information page.

2017.04.01    A project to measure specific antibodies in blood samples (4-year-old children) for the "National Survey on Children's Health and the Environment (Eco Chill Survey) Detailed Survey" conducted by the Ministry of the Environment, Japan has been adopted.

2017.02.21     Certified AMERIC as a "University of Tokushima Venture" by the University of Tokushima National University Corporation.

2016.12.06    AMERIC was approved by Ministry of Economy, Trade and Industry as an in vitro diagnostic drug manufacturer and distributor.

2016.10.01    A project of SF-10 adjuvant has been adopted by the National Institute of Biomedical Innovation, Japan Agency for Medical Research and Development (NIBRD) for the FY 2008 Industry-Academia Collaboration Medical Innovation Creation Program - Basic Scheme (ACT-M).

2016.08.26    The trademark "IgSensor AMERIC🄬" was registered to Japan Patent Office.

2016.06.19    We exhibited the data of “efficacy of the binding-avidity of IgE in allergic reaction sensitivity” at the 65th Annual Meeting of the Japanese Society of Allergology (Tokyo International Forum: June 17-19, 2017).

2015.06.19     A project of DCP microarray has been adopted by the FY2014 Supplementary Manufacturing, Commerce and Service Innovation Subsidy of Tokushima Prefecture.

2015.05.28    We exhibited the data of “DCP microarray for allergy diagnosis” at the 64th Annual Meeting of the Japanese Society of Allergology (Grand Prince Hotel New Takanawa International Pavilion Pamir: May 26th-28th, 2014).

2015.05.13     AMERIC Okinosu Laboratory has been registered as an in vitro diagnostics manufacturer to the Ministry of Economy, Trade and Industry in Japan.

2015.04.01    A project to measure specific antibody measurement work (for 2-year-old children) in blood samples for the Ministry of the Environment's "National Survey on Children's Health and the Environment (Eco-Children Survey) Detailed Survey" has been adopted.

2015.03.16    AMERIC Okinosu Sanitary Laboratory has been registered as a sanitary laboratory to the Ministry of Health, Labour and Welfare in Japan.

2014.05.11    We exhibited the data of “DCP microarray for allergy diagnosis” at the 26th Spring Clinical Conference of the Japanese Society of Allergology (Kyoto International Conference Center: May 9-11, 2014).

2014.05.02    Exhibiting at the 26th Japanese Society of Allergology Spring Clinical Conference (Kyoto International Conference Center: May 9-11, 2014).

2013.11.07    Received a subsidy for the establishment of advanced technology demonstration and evaluation facilities (public offering in September 2012). (DCP chip-related matters)

2013.10.24    Won the Tokushima New Business Support Award 2013 Grand Prize at the Tokushima Business Challenge Messe 2013!

2013.10.24    We exhibited “DCP microarray technology” and won the Tokushima New Business Support Award 2013 Grand Prize at the Tokushima Business Challenge Messe 2013.

2013.04.01     Due to the relocation of AMERIC head office, our address, telephone number, and fax number have changed.

2012.10.01     In collaboration with Taisho Toyama Pharmaceutical Co., Ltd., we established the endowed chair department of "Division of pathology for Infectious Disease and Host Defense" at the Research Institute, Tokushima University. Specially Appointed Professor Hiroshi Kido (April 2013) and Specially Appointed Assistant Professor Etsuhisa Takahashi (October 1, 2012) were appointed to the position.

2012.06.16     The calculation software for AMERIC-ATP(T)Kit has been updated with the new 1.2 version.

2012.04.19    Calculation software for AMERIC-ATP(T)Kit has been added to the download page.

2012.03.28    An article on the AMERIC-ATP(T)Kit for tissue extraction is published on page 23 of the April issue of Wako's public relations magazine "Bio Window" No. 116.

2012.03.23    AMERIC and its trademark are registered to the Japan Patent Office.

2012.02.27    An article on the newly developed AMERIC-ATP assay Kit has been published on page 16 of the March issue of Wako's public relations magazine "Bio Window" No. 115.

2011.12.19    AMERIC website is launched.

2011.11.30    Commissioned the sale of ATP testing reagents and have begun sales.

2011.10.17     trademark "AMERIC" of our English company name, "Applied Medical Enzyme Research Institute Corporation" has been announced.

2011.09.15    Granted authorization to manufacture poisonous and hazardous substances.

2011.09.14    Approved as a general distributor of poisonous and hazardous substances by the Ministry of Health, Laboure and Welfare in Japan.

2010.05.27    Founded Applied Medical Enzyme Research Institute Corporation(AMERIC).